Forecasting The Future: 14 Analyst Projections For Praxis Precision Medicine
Portfolio Pulse from Benzinga Insights
Analysts have varied ratings for Praxis Precision Medicine (NASDAQ:PRAX), with a mix of bullish and somewhat bullish sentiments. The average 12-month price target has increased by 3.45% to $144.64. Despite challenges like a 54.29% revenue decline, PRAX shows strong ROE and low debt-to-equity ratio.

September 04, 2024 | 9:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Praxis Precision Medicine (NASDAQ:PRAX) has received mixed analyst ratings, with a majority being bullish. The average price target has increased by 3.45% to $144.64. Despite a significant revenue decline, the company shows strong ROE and a healthy debt-to-equity ratio.
The increase in the average price target and the majority of bullish ratings suggest a positive short-term outlook for PRAX. The company's strong ROE and low debt-to-equity ratio are positive financial indicators, despite the revenue decline.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100